SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels.
| Author | |
|---|---|
| Abstract |
:
Cardiovascular calcification (CVC) is a major concern in hemodialysis (HD) and the loss of endogenous modulators of calcification seems involved in the process. Phytate is an endogenous crystallization inhibitor and its low molecular mass and high water solubility make it potentially dialyzable. SNF472 (the hexasodium salt of phytate) is being developed for the treatment of calciphylaxis and CVC in HD patients. We aimed to verify if phytate is lost during dialysis, and evaluate SNF472's behaviour during dialysis. |
| Year of Publication |
:
2018
|
| Journal |
:
Journal of nephrology
|
| Date Published |
:
2018
|
| ISSN Number |
:
1121-8428
|
| URL |
:
https://dx.doi.org/10.1007/s40620-018-0471-9
|
| DOI |
:
10.1007/s40620-018-0471-9
|
| Short Title |
:
J Nephrol
|
| Download citation |
